2019
Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors
Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer E, Ng K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors. JNCI Cancer Spectrum 2019, 4: pkz096. PMID: 32090192, PMCID: PMC7025659, DOI: 10.1093/jncics/pkz096.Peer-Reviewed Original ResearchBreast cancer survivorsPhase II trialCancer survivorsControl armII trialInsulin levelsRandomized phase II trialInsulin-like growth factor-1Insulin-like growth factorHomeostatic model assessmentCombination of exerciseSignificant weight lossGrowth factor-1Combination armMetformin useSecondary outcomesStandard therapyPrimary outcomeIntervention armInsulin resistanceDisease outcomeModality interventionsAnthropometric measurementsMetabolic markersMetabolic biomarkers
2016
Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer
Yu H, Irwin M. Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer. Energy Balance And Cancer 2016, 11: 251-264. DOI: 10.1007/978-3-319-41610-6_11.Peer-Reviewed Original ResearchDNA methylationTumor suppressor genePhysical activityEpigenetic regulationSuppressor geneCancer riskGenome-wide methylationBetter patient survivalBreast cancer patientsPro-inflammatory cytokinesBreast cancer riskSex steroid hormonesLower cancer riskMitogenic growth factorsEntire genomeMolecular mechanismsInsulin resistancePatient survivalCancer patientsMethylationMore profound impactsCancer preventionBreast cancerDisease outcomeHealthy individuals